Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Analyst Coverage
A.G.P. / Alliance Global Partners
James Molloy
jmolloy@allianceg.com
(212) 624-2060
D. Boral Capital
Jason Kolbert
jkolbert@dboralcapital.com
H.C. Wainwright & Co.
Raghuram Selvaraju, Ph.D.
rselvaraju@hcwresearch.com
(212) 916-3966
Maxim Group LLC
Jason McCarthy, Ph.D.
jmccarthy@maximgrp.com
(212) 895-3556
Roth Capital Partners
Boobalan Pachaiyappan, Ph.D.
bpachaiyappan@roth.com
The Benchmark Company
Bruce Jackson
bjackson@benchmarkcompany.com
(212) 312-6792
Zacks Investment Research, Inc.
John Vandermosten, Ph.D.
jvandermosten@zacks.com